Medicare AdvantageAdministrativeLow impact
MA11.014g, Debridement of Mycotic and Symptomatic Non-Mycotic Hypertrophic Toe Nails
Independence Blue Cross·NJ · Podiatry, Dermatology, General Practice +1 more·Medical Policy
We identified it
Jun 19, 2026
Summary
Independence Blue Cross reissued MA11.014g on 04/02/2025 to communicate the Company's continuing position on debridement of mycotic and symptomatic non-mycotic hypertrophic toenails. This is a policy reissuance with no material coverage changes—the same medical necessity criteria, billing codes, and ICD-10 diagnosis codes remain in effect. Billing teams should verify their systems reflect the current policy version (MA11.014h supersedes MA11.014g) and confirm all applicable diagnosis codes are captured at claim submission.
Action Required
No immediate action required. This is a policy reissuance confirming the Company's continuing position with no substantive coverage changes. Billing team should: (1) Verify claims processing systems reflect policy version MA11.014h (the current active version; MA11.014g is superseded and removed from the portal); (2) Confirm that nail debridement claims (CPT 11720, 11721) are submitted with required ICD-10 diagnosis codes (L60.8 paired with secondary infection/pain codes such as B37.2, L02.611, L02.612, L02.619, L03.031, L03.032, or qualifying systemic illness codes); (3) Ensure prior documentation of qualifying medical conditions is attached to claims. No workflow changes are necessary unless your current system references the older MA11.014g version.